N
NBIX icon

Nuveen’s Neurocrine Biosciences NBIX Stock Holding History

Nuveen’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.4M Buy
443,052
+156,267
+54% +$20.7M 0.02% 581
2025
Q4 		$40.7M Buy
286,785
+41,819
+17% +$6.06M 0.01% 749
2025
Q3 		$34.4M Buy
244,966
+16,104
+7% +$2.18M 0.01% 807
2025
Q2 		$28.8M Sell
228,862
-57,634
-20% -$6.61M 0.01% 886
2025
Q1 		$31.7M Buy
286,496
+18,516
+7% +$2.35M 0.01% 848
2024
Q4 		$36.6M Sell
267,980
-77,597
-22% -$9.6M 0.01% 808
2024
Q3 		$39.8M Sell
345,577
-1,916
-0.6% -$263K 0.01% 771
2024
Q2 		$47.8M Sell
347,493
-9,701
-3% -$1.33M 0.01% 646
2024
Q1 		$49.3M Sell
357,194
-3,329
-0.9% -$455K 0.01% 638
2023
Q4 		$47.5M Sell
360,523
-4,535
-1% -$522K 0.02% 624
2023
Q3 		$41.1M Buy
365,058
+40,884
+13% +$4.31M 0.01% 637
2023
Q2 		$30.6M Buy
324,174
+80,416
+33% +$7.86M 0.01% 817
2023
Q1 		$24.7M Sell
243,758
-4,063
-2% -$423K 0.01% 902
2022
Q4 		$29.6M Sell
247,821
-32
-0% -$3.75K 0.01% 805
2022
Q3 		$26.3M Sell
247,853
-6,938
-3% -$704K 0.01% 844
2022
Q2 		$24.8M Buy
254,791
+5,529
+2% +$510K 0.01% 896
2022
Q1 		$23.5M Buy
249,262
+4,453
+2% +$377K 0.01% 1087
2021
Q4 		$20.9M Sell
244,809
-33,700
-12% -$3.1M 0.01% 1211
2021
Q3 		$26.7M Sell
278,509
-87,751
-24% -$8.29M 0.01% 1068
2021
Q2 		$35.6M Sell
366,260
-84,124
-19% -$8.06M 0.01% 944
2021
Q1 		$43.8M Sell
450,384
-15,901
-3% -$1.67M 0.01% 800
2020
Q4 		$44.7M Sell
466,285
-90,204
-16% -$8.71M 0.02% 747
2020
Q3 		$53.5M Sell
556,489
-33,108
-6% -$3.83M 0.02% 557
2020
Q2 		$71.9M Sell
589,597
-31,719
-5% -$3.51M 0.03% 457
2020
Q1 		$53.8M Sell
621,316
-70,512
-10% -$6.9M 0.03% 475
2019
Q4 		$74.4M Sell
691,828
-115,889
-14% -$12.1M 0.03% 512
2019
Q3 		$72.8M Buy
807,717
+40,939
+5% +$3.82M 0.03% 495
2019
Q2 		$64.7M Buy
+766,778
New +$63M 0.03% 564
2017
Q2 		– Sell
-14,464
Closed -$626K – 1235
2017
Q1 		$626K Buy
14,464
+763
+6% +$32.7K ﹤0.01% 1112
2016
Q4 		$530K Hold
13,701
– – ﹤0.01% 1304
2016
Q3 		$694K Buy
13,701
+2,737
+25% +$136K ﹤0.01% 1182
2016
Q2 		$498K Sell
10,964
-22,643
-67% -$1.04M ﹤0.01% 1181
2016
Q1 		$1.33K Sell
33,607
-5,207
-13% -$207K 0.01% 915
2015
Q4 		$2.2K Buy
38,814
+8,132
+27% +$413K 0.01% 740
2015
Q3 		$1.22K Sell
30,682
-6,522
-18% -$315K 0.01% 987
2015
Q2 		$1.78K Buy
37,204
+1,532
+4% +$65K 0.01% 879
2015
Q1 		$1.42M Buy
+35,672
New +$1.28M 0.01% 1015

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen's NBIX Position: Q1 2026 in Review

Nuveen increased its Neurocrine Biosciences (NBIX) stake by 54% in Q1 2026, buying an estimated $20.7M and bringing the position to 443,052 shares worth $58.4M. The position accounts for 0.02% of the portfolio, ranked #581.

Nuveen first reported a position in NBIX in Q1 2015 and has held it in 37 quarters since. The position peaked at $74.4M in Q4 2019. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Nuveen held 443,052 shares of Neurocrine Biosciences worth $58.4M as of Q1 2026.
  • Nuveen bought 156,267 Neurocrine Biosciences shares in Q1 2026, an estimated $20.7M.
  • Neurocrine Biosciences made up 0.02% of Nuveen's portfolio in Q1 2026, its #581 holding.
  • Nuveen first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 37 quarters since.
  • Nuveen's Neurocrine Biosciences position peaked at $74.4M in Q4 2019.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.